Search PubMed⌕ Search

Biomedical subjects

K Tamura

Publications and source records attributed to K Tamura.

At least 1,171 records · Page 65Linked to original sources
PubMed1986

Simple determination of forphenicinol in human plasma and erythrocytes by HPLC with native fluorescence detection.

A high performance liquid chromatographic method is described for monitoring forphenicinol, a possible therapeutic drug for cancer and muscular dystrophy, in human plasma and erythrocytes. Forphenicinol in the deproteinized samples was separated from interfering biogenic substances on an aminopropyl-bonded silica (Unicil NH2) column within 10 minutes with isocratic elution, and determined with fluorescence detection. The detection limits for forphenicinol in plasma and erythrocytes are 65 pmol (12.8 ng)/ml and 160 pmol (31.5 ng)/ml, respectively, corresponding to 2 pmol each in a 100 microliters injection volume. The method is very simple, and sensitive enough to permit the quantification of forphenicinol in the blood samples from man dosed with forphenicinol.

Adjuvants, Immunologic↗
PubMed1986

Development and use of a remote-controlled mitral valve.

A remote-controlled mitral valve was designed and constructed to occlude the mitral or tricuspid orifice at any time in the cardiac cycle. It is used to study ventricular properties in the anesthetized dog by controlling ventricular filling, atrial properties by controlling atrial emptying and interaction of the two chambers by uncoupling them. The device can produce transient or steady-state perturbations in filling volume which make possible studies of intrinsic control of cardiac output. When filling volume is transiently reduced, stroke volume and end-systolic volume are reduced. A compensatory increase in stroke volume of the next cycles occurs due to increased ventricular preload and reduced afterload. The compensation continues until the lost stroke volume is regained, at which time the system returns to its previous steady state.

Animals↗
PubMed1986

Reinvestigation of compound X, a suspected biotin intermediate: identification of N-formyl derivatives of biotin and dethiobiotin.

Compound X, reported as an intermediate in the biosynthesis of biotin from dethiobiotin (DTB) (Biochem. Biophys. Res. Commun., 88, 312 (1979)), was found to contain N-formyl DTB and biotin. The methyl ester of N-formyl biotin was considered to be a product from the biotin, which was biosynthesized from DTB by resting cells of E. coli C 124, through treatment with diazomethane in the presence of a trace amount of formic acid after Dowex 1X2 column chromatography. NMR analysis revealed that biotin was formylated at 1'-N. N-Formylated DTB and biotin are new biotin derivatives.

Biotin↗
PubMed1986

[Side effects of peplomycin].

Twenty-three patients with squamous cell carcinoma were treated with a combination chemotherapy consisting of cisplatin, vincristine, and peplomycin. Overall response rate was over 70% including complete disappearance of tumors in one patient. Peplomycin was given by continuous i.v. or s.c. infusion using a micro-infusion pump. All the patients experienced some degree of nausea, vomiting, and hair loss. Phlebitis and induration of injection sites with subsequent local pigmentation were frequently encountered. Nausea and vomiting were caused mainly by cisplatin, but more than 60% of the patients experienced transient increase of anorexia or nausea in the period of peplomycin administration. Eruption with skin excoriation or pigmentation along scratch dermatitis were seen in 5 patients. These side effects were well tolerated, and high fever which is commonly observed in one-shot therapy did not develop in any patient. Pulmonary fibrosis was also not seen. Peplomycin should be given by low-dose continuous infusion because of its low toxicity and comparable antineoplastic activity to one-shot therapy.

Aged↗
PubMed1986

[Successful chemotherapy in undescended testicular and extragonadal germ cell tumors: report of 2 cases].

Two patients with advanced germ cell tumor who entered complete remission following intensive combination chemotherapy, radiation therapy and surgical intervention are reported. A 28-year-old businessman presented with abdominal pain and masses associated with an elevated HCG level for which he underwent exploratory laparotomy. Large retroperitoneal masses were found and microscopical examination of the masses were revealed seminoma. Three courses of combination chemotherapy consisting of CDDP, VLB and PEP were given to the patient followed by radiation therapy to the parailiac, paraaortic, mediastinal and supraclavicular lymph nodes with boost irradiation to the paraaortic lymph nodes where the large masses were located. The other patient was a 21-year-old student who developed sharp precordial chest pain which proved to be due to a large mediastinal mass accompanied by an elevated AFP level. He was treated with radiation therapy to the mediastinum, surgical resection and combination chemotherapy. However, he showed recurrence in the lungs associated with rising AFP levels, and was given a salvage chemotherapy consisting of 3 courses of CDDP, ADR, PEP and Etoposide. Both patients were successfully treated with combined modalities of treatment including intensive chemotherapy and have been off therapy without recurrence for over 12 and 4 months, respectively.

Adult↗
PubMed1986

[Peplomycin for hypercalcemia in a patient with adult T cell leukemia].

A 60-year-old man with adult T cell leukemia had been suffering from intractable hypercalcemia resistant to saline hydration, intravenous administration of furosemide, elcatonin, prednisolone and phosphate, and also hemodialysis. Since there was one report suggesting that bleomycin could act as an anticalcemic agent, peplomycin, a new derivative of blerivative of bleomycin, was given at a dose of 10 mg/day by continuous intravenous infusion for 3 days and rapid normalization of serum calcium and creatinine levels resulted. The mechanism of this antihypercalcemic effect is not clear, but peplomycin directly inhibit bone resorption.

Bleomycin↗
PubMed1986

[Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma].

A group study was conducted to investigate the effect of intra-hepatic arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma(HCC). Sixty-four patients were entered into the study. There were 51 males and 13 females, with an age range from 32 to 79 years, the average being 59.1 years. Fifty-four patients had associated cirrhosis of the liver. Epirubicin at a dose of 60-90 mg/m2 was infused as a bolus into the hepatic artery 1 to 4 times (average 1.8) at an interval of 3 weeks to 3 months. Tumor size was properly evaluated in 53 patients. There were 1 CR, 7 PR, 7 MR, 27 NC, and 11 PD. Thus, the response rate (CR + PR) was 15.1%. Seventeen patients are still alive 305 to 720 days (mean 505 days) after the initial treatment. The most common side effects of this drug were bone marrow suppression, gastrointestinal complaints, and alopecia. Cardiac toxicity was negligible at the doses used in this study. A retrospective comparison of the present results with those for patients treated by intra-arterial administration of doxorubicin demonstrated that epirubicin is more effective than doxorubicin in terms of survival rate. The current study indicates that epirubicin may be a promising alternative in the treatment of HCC. The appropriate dosage of the drug and the interval for infusion are to be elucidated. Also, the combination of epirubicin with other cytostatic drugs is open for study.

Adult↗
PubMed1986

Antitumor effect of recombinant human interferon alpha A/D on Meth-A sarcoma in mice.

Recombinant human interferon alpha A/D (IFN alpha A/D) is known to be as active on murine cells as on human cells. We studied the antitumor effect of pure IFN alpha A/D on Meth-A sarcoma subcutaneously transplanted into female syngeneic BALB/c mice. When administered systematically (intraperitoneally), IFN alpha A/D was only marginally (but significantly, P less than 0.05) effective in inhibiting tumor growth. With intralesional injection, however, IFN alpha A/D strongly suppressed the growth of Meth-A sarcoma, even leading to complete tumor regression and to subsequent immunity to Meth-A sarcoma cells in the host mice when the treatment was started early after tumor transplantation and with a high IFN alpha A/D dose. We also found that treatment of mice with IFN alpha A/D increased the level of serum alpha 1-acid glycoprotein, one of the acute-phase proteins.

Animals↗
PubMed1986

Antitumor activity of protein-bound polysaccharide from Cordyceps ophioglossoides in mice.

The effects of protein-bound polysaccharide (SN-C) extracted from Cordyceps ophioglossoides on the growth of transplanted allogeneic and syngeneic murine tumors were studied. SN-C given by intraperitoneal administration suppressed the growth of sarcoma-180 transplanted subcutaneously in mice. Intraperitoneal administration of SN-C also caused a significant prolongation of the life span of ICR mice inoculated intraperitoneally with Ehrlich carcinoma, and C3H/He mice inoculated intraperitoneally with a syngeneic tumor (X-5563). SN-C showed a significant cytocidal effect on cultured tumor cells. SN-C did not affect delayed-type hypersensitivity (DTH) in normal mice, but restored the depressed capacity to raise DTH in tumor-bearing mice. These results suggested that SN-C may exert both direct and host-mediated antitumor effects.

Animals↗
PubMed1986

[Phase II study of epirubicin on breast cancer: a cooperative group study].

A phase II multicenter clinical study of epirubicin, a new anthracycline anticancer agent, was carried out in 46 patients with advanced breast cancer. The treatment schedule consisted of either 60 mg/m2 every three weeks or 40 to 50 mg/m2 on day 1 and day 8 every four weeks. Objective responses were observed in 23.7% of 38 evaluable patients (1 CR and 8 PR). Response rates according to previous chemotherapy were 50.0% (4/8) in previously non-treated patients and 36.4% (4/11) in patients previously treated with non-anthracyclines. The major adverse effect was bone-marrow suppression; leukopenia was observed in 82.1% of patients, anemia in 53.8% and thrombocytopenia in 20.0%. Other toxicities frequently observed were anorexia (55.0%), nausea-vomiting (55.0%) and alopecia (66.7%), but these seemed to be milder than those produced by doxorubicin.

Adult↗
PubMed1986

[A phase II study of epirubicin in malignant lymphoma].

A new anthracycline analog, epirubicin (4'-epi-Adriamycin) was evaluated at eleven institutes in a phase II clinical study in patients with malignant lymphoma. Epirubicin was administered intravenously mainly with using the following two regimens; 50 to 60 mg/m2 every three weeks and 40 mg/m2 weekly. A total of 46 cases were entered into the study and 41 cases were evaluable. Clinical responses, complete plus partial remissions, were observed in 27 cases (65.9%) with 8 of these showing complete remission. There was no significant difference of response between the two regimens. Response rates taking into account previous chemotherapy were 90.9% (10/11) in previously nontreated cases, 61.9% (8/13) in cases previously treated with non-anthracyclines and 52.9% (9/17) in cases treated with anthracyclines. The major adverse effect was bone marrow suppression; leukopenia was observed in 83.8%, anemia in 60.5% and thrombocytopenia in 15.4%. Other adverse effects frequently observed were anorexia (59.0%), nausea-vomiting (48.8%) and alopecia (55.6%). These adverse effects seemed milder than those produced by doxorubicin. The results indicated that epirubicin seemed to be a markedly useful drug against malignant lymphoma.

Adult↗
PubMed1986

[A case of adult T-cell leukemia responding to recombinant interferon-beta (GKT-beta)].

Interferon-beta (GKT-beta) was administered to a patient with adult T-cell leukemia (ATL), presumably of acute type, with a marked organ infiltration and increases in serum calcium, LDH and bilirubin. The therapy produced a fall in the number of peripheral blood abnormal lymphocytes, disappearance of jaundice, reduction in the degree of hepatomegaly and splenomegaly and a remarkable improvement of general condition with a performance status of grade 3 improving to grade 1. The response has been maintained for more than seven months. Dose, schedule and criteria for drug discontinuation are matters for further investigation.

Bilirubin↗